Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
FR00140048X2
Thu, 23.06.2022
Ikonisys SA
First sale of Ikoniscope20
Ikonisys has announced the first sale of its Ikoniscope20 microscope
solution together with reagents. The sale is, in our view, a first proof
that the commercialization strategy of migrating existing users of
Ikonisys' former Ikoniscope Gen1 platform into users of the state-of-art
Ikoniscope20 technology is correctly c [ … ]
Mon, 09.05.2022
Ikonisys SA
New significant shareholder through convertible bond
With the issuance of a de facto mandatory convertible bond, Ikonisys has,
in our view, found a smart solution to one of its major problems: Funding
the market entry of Ikoniscope20 in the US and Europe and funding the
further development of the microscope platform into a state-of-the-art
artif [ … ]
Wed, 09.02.2022
Ikonisys SA
Important client-win in Italy
After the first sale of the new-gen microscope, the Ikoniscope20, to one of
the biggest genetic laboratories in Italy, we confirm our Buy rating for
the shares of Ikonisys and our three-stage discounted cash flow entity
model (primary valuation method) share price target of EUR 7.70.
Ikonisys announced the sale an [ … ]
Tue, 25.01.2022
Ikonisys SA
Restart of a technology leader in laboratory automation
With a share price target of EUR 7.70 and an expected share price
performance of 176.0%, we initiate research coverage on the shares of
Ikonisys SA with a Buy rating. Our price target is derived from a threestage
discounted cash flow entity model (primary valuation method), for
which we ca [ … ]